49850-32-0

Basic information

• Product Name: ethyl 4-(1H-indol-3-yl)butanoate
• CAS NO: 49850-32-0
• Molecular Formula: C₁₄H₁₇NO₂
• Molecular Weight: 231.2903
• Mol File: 49850-32-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 393.8°C at 760 mmHg
• Flash Point: 191.9°C
• Density: 1.132g/cm³
• Vapor Pressure: 2.08E-06mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: ethyl 4-(1H-indol-3-yl)butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(1H-indol-3-yl)butanoate(49850-32-0)
• EPA Substance Registry System: ethyl 4-(1H-indol-3-yl)butanoate(49850-32-0)

Safety Data

• Hazardous Substances Data: 49850-32-0(Hazardous Substances Data)

Upstream product

• 133-32-4 4-indol-3-yl-butyric acid 
• 64-17-5 ethanol 
• 5299-60-5 6-hydroxy-hexanoic acid ethyl ester 
• 502-44-3 hexahydro-2H-oxepin-2-one 
• 27983-42-2 5-carboethoxypentanal 
• 100-63-0 phenylhydrazine 
• 64802-52-4 4-(2,3-dihydro-indol-3-yl)-butyric acid ethyl ester 
• 59-88-1 phenylhydrazine hydrochloride 

Downstream Products

• 221188-37-0 4-[1-(4-fluoro-benzyl)-1H-indol-3-yl]-butyric acid ethyl ester 
• 903138-79-4 4-[1-(4-fluoro-benzyl)-1H-indol-3-yl]-butyric acid 
• 904230-60-0 N'-(4-fluorobenzylidene)-4-(1H-indol-3-yl)butanehydrazide 
• 904219-89-2 N'-(4-chlorobenzylidene)-4-(1H-indol-3-yl)butanehydrazide 
• 904249-44-1 N'-(3-chlorobenzylidene)-4-(1H-indol-3-yl)butanehydrazide 
• 898172-42-4 N'-(3,4-dichlorobenzylidene)-4-(1H-indol-3-yl)butanehydrazide 
• 904249-32-7 N'-(4-methoxybenzylidene)-4-(1H-indol-3-yl)butanehydrazide 
• 902351-39-7 N'-(2,4,6-trimethoxybenzylidene)-4-(1H-indol-3-yl)butanehydrazide 
• 1449036-06-9 N'-(4-(3,5,6-trichloropyridin-2-yloxy)benzylidene)-4-(1Hindol-3-yl)butanehydrazide 
• 1449036-07-0 5-(3-(1H-indol-3-yl)propyl)-2-phenyl-1,3,4-oxadiazole 
• 1449036-14-9 5-(3-(1H-indol-3-yl)propyl)-2-(4-fluorophenyl)-1,3,4-oxadiazole 
• 1449036-16-1 5-(3-(1H-indol-3-yl)propyl)-2-(4-chlorophenyl)-1,3,4-oxadiazole 
• 1449036-18-3 5-(3-(1H-indol-3-yl)propyl)-2-(3-chlorophenyl)-1,3,4-oxadiazole 
• 1449036-21-8 5-(3-(1H-indol-3-yl)propyl)-2-(3,4-dichlorophenyl)-1,3,4-oxadiazole 

Relevant articles and documents

Rhodium-Catalyzed C?H Functionalization of Indoles with Diazo Compounds: Synthesis of Structurally Diverse 2,3-Fused Indoles

A Rhodium-catalyzed C2-H functionalization of indoles with diazo compounds, followed by intramolecular nucleophilic addition to C=O or C=C bonds, is reported for divergent synthesis of 2,3-fused indoles. Besides acceptor/acceptor diazo compounds, donor/acceptor diazo compounds are broadly tolerated, giving various 2,3-fused indoles with perfect diastereocontrol. Notably, a selective C?H dialkylation reaction at C2 and C7 position of indoles has also been developed by simply changing the reaction conditions. This environmentally benign transformation proceeds under mild conditions and gives dinitrogen as the only by-product. (Figure presented.).

Synthesis of CF3-Containing Spirocyclic Indolines via a Red-Light-Mediated Trifluoromethylation/Dearomatization Cascade

A red-light-mediated nPr-DMQA+-catalyzed cascade intramolecular trifluoromethylation and dearomatization of indole derivatives with Umemoto's reagent has been developed. This protocol provides a facile and efficient approach for the construction of functionalized and potentially biologically important CF3-containing 3,3-spirocyclic indolines with moderate to high yields and excellent diastereoselectivities under mild conditions. The success of multiple gram-scale (1 and 10 g) experiments further highlights the robustness and practicality of this protocol and the merit of the employment of red light. Mechanistic studies support the formation of a crucial CF3 radical species and a dearomatized benzyl carbocation intermediate.

METHODS AND MATERIALS FOR INCREASING OR MAINTAINING NICOTINAMIDE MONONUCLEOTIDE ADENYLYL TRANSFERASE-2 (NMNAT2) POLYPEPTIDE LEVELS

This document provides methods and materials for increasing or maintaining NMNAT2 polypeptide levels within cells. For example, compounds (e.g., organic compounds) having the ability to increase or maintain NMNAT2 polypeptide levels within cells, formulations containing compounds having the ability to increase or maintain NMNAT2 polypeptide levels within cells, methods for making compounds having the ability to increase or maintain NMNAT2 polypeptide levels within cells, methods for making formulations containing compounds having the ability to increase or maintain NMNAT2 polypeptide levels within cells, methods for increasing or maintain NMNAT2 polypeptide levels within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in NMNAT2 polypeptide levels are provided (or for preventing said condition).